Finance

Lists
2F50:FRA
Scinai Immunotherapeutics Ltd - ADR
-100.00%
(-2.26) 1D
Sep 10, 11:45:58 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 2F50...
Mkt. cap
951.94K
Volume
0.00
52-wk high
€136.00
52-wk low
€18.20
No. of employees
45
Mkt. cap
951.94K
Volume
0.00
52-wk high
€136.00
52-wk low
€18.20
No. of employees
45
Profile
BiondVax Pharmaceuticals Ltd. is an Israeli biopharmaceutical company focused on developing and manufacturing immunotherapeutic products, primarily for the treatment of infectious diseases and autoimmune diseases. In collaboration with the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen, both in Germany, BiondVax develops nanosized antibody therapies for diseases such as COVID-19, asthma and psoriasis. Wikipedia
About Scinai Immunotherapeutics Ltd - ADR
CEO-
Employees45
FoundedJan 1, 2003
Headquarters-
SectorBiotechnology
Websitescinai.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
269.00K
269.00K
489.00K
460.00K
Cost of goods sold
960.00K
960.00K
1.61M
1.71M
Cost of revenue
960.00K
960.00K
1.61M
1.71M
Research and development expenses
566.00K
566.00K
628.00K
211.00K
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
632.50K
632.50K
721.00K
683.00K
Operating expense
1.20M
1.20M
1.35M
894.00K
Total operating expenses
2.16M
2.16M
2.96M
2.61M
Operating income
-1.89M
-1.89M
-2.47M
-2.15M
Other non operating income
-3.50K
-3.50K
-
-
EBT including unusual items
-2.09M
-2.09M
3.58M
-2.00M
EBT excluding unusual items
-2.09M
-2.09M
-2.58M
-2.25M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-2.09M
-2.09M
3.58M
-2.00M
Net profit margin
-775.65%
-775.65%
731.49%
-435.43%
Earnings per share
-
-
-
-
Interest and investment income
16.00K
16.00K
-
-
Interest expense
-
-
-112.00K
-102.00K
Net interest expenses
16.00K
16.00K
-112.00K
-102.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-1.53M
-1.53M
-2.01M
-1.56M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google apps